RCKT
RocketCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
KRESLADI approval removes a major regulatory overhang, adds a PRV monetization lever, and leaves upside tied to cardiac programs if Danon re-derisks and PKP2 continues to show biologic activity [#8-K-2026-03-27] [#10-K-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Danon RP-A501 remains the main downside source if the next three-patient review is mixed or reveals recurring safety/tolerability issues.
Momentum
9
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.60 · Bull $7.50 · Bear $2.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.23
Why
Momentum9 · Δ7d -0.6
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
9
34% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
+0.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
0.0
Δ21d
+30.2
Why this grade
Composite grade C. Momentum 9.2 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$315.57M
Beta
0.48
Shares Out
108.22M
P/E (TTM) · Derived
-1.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.55
Rev YoY
-
EPS YoY
+36.3%
Gross Margin
-
Op Margin
-
Net Debt
-$351.1M
Current Ratio
7.30
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology